^
Association details:
| Biomarker: | AFP elevation |
|---|---|
| Cancer: | Hepatocellular Cancer |
| Drug: | sorafenib (Multi-tyrosine kinase inhibitor, pan-RAF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Study of TAC-101 as Second Line Treatment in Patients With Advanced Hepatocellular Carcinoma Who Received Sorafenib as First Line Therapy
Excerpt:
...AFP is a tumor marker for hepatocellular carcinoma and elevations in AFP values could precede clinical deterioration and tumor recurrence in participants. ...
Trial ID:
Source:
Title:
Efficacy of sequential sorafenib plus hepatic arterial infusion chemotherapy in patients with Barcelona Clinic Liver Cancer stage B and C hepatocellular carcinoma: a retrospective single-institution study
Excerpt:
The crude median OS was 17.1 months (95% confidence interval [CI]: 14.3–25.6 months) in the combination group compared with 9.7 months (95% CI: 7.0–15.1 months) in the control group, with one-year survival rates of 74.2% (95% CI: 51.2–87.6%) and 44.2% (95% CI: 31.7–56.0%), respectively (p = 0.01). Univariate analysis revealed that OS was significantly associated with the ECOG-PS, BCLC stage, baseline AFP level (≥ 400 ng/ml), and combination therapy...According to multivariate regression analysis, combination therapy (hazard ratio [HR]: 0.521, 95% CI: 0.297–0.915, p = 0.02) and the AFP level (≥ 400 ng/ml) (HR: 2.221, 95% CI: 1.338–3.685, p = 0.002) were significant determinants of OS....
DOI:
10.5114/wo.2018.78948
